Liquid Biopsy Panels Market By Biomarker Type (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Exosomes & Extracellular Vesicles (EVs), MicroRNA, Cell-free DNA, Proteins, Methylated DNA Markers), By Panel Type (Single-Gene Panels, Multi-Gene Panels, Tumor-Specific Panels, Comprehensive Genomic Panels, Custom Panels), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Beads, Emulsion, Amplification, and Magnetics, Droplet Digital PCR, Massively Parallel Sequencing, Microarrays, Immunoassays), By Application (Cancer Diagnostics, Treatment Selection & Monitoring, Early Cancer Screening & Risk Assessment, Recurrence & Prognosis Prediction, Prenatal Testing, Transplant Rejection Monitoring, Infectious Disease Monitoring), By Sample Type (Blood, Urine, Saliva, Cerebrospinal Fluid, Others), and By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Biopharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs)), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Liquid Biopsy Panels Market in the coming years?

The Liquid Biopsy Panels Market accounted for USD 4.35 Billion in 2024 and USD 4.93 Billion in 2025 is expected to reach USD 17.33 Billion by 2035, growing at a CAGR of around 13.39% between 2025 and 2035. The liquid biopsy panels market is the commercial sphere that deals with the construction and marketing of diagnostic experiments to analyse biomarkers, e.g., circulating tumour DNA, cells, or RNA in human fluids like blood. The panels allow non-invasive identification, follow-up, and treatment of the illnesses, mostly cancer, giving real-time data of genetic alteration and tumour kinetics. This market is motivated by an increasing need for early detection, customised medicine, and less agonising procedures than the conventional tissue biopsies. The spread of this market is being caused by the growth of molecular biology and genomics, and the prevalence of cancer all over the world.

What do industry experts say about the Liquid Biopsy Panels market trends?

“Liquid biopsy, and especially plasma ctDNA, can be used in many clinical settings where tissue is not applicable, such as the detection of minimal residual disease (MRD)… We anticipate the opportunities for liquid biopsy will continue to expand.”

• Dr. Christian Rolfo, MD, PhD, MBA, Associate Director for Clinical Research, Mount Sinai, NY

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Liquid Biopsy Panels market?

How does rising cancer prevalence boost liquid biopsy panels market?

The increasing cancer incidences all over the world are crucial factors that stimulate the liquid biopsy panels market. The World Health Organisation (WHO) estimated that during the year 2022 alone, around 20 million fresh cases were diagnosed worldwide, contextually as one of the highest levels ever recorded. There are more than 18 million cancer survivors in the United States, according to the National Cancer Institute in 2022. This huge number of cancer patients emphasises the growing demand for effective and non-invasive diagnostic tools.

Real-time information on tumour characteristics can be achieved by liquid biopsies that deconstruct circulating tumour DNA in blood samples, as opposed to the inherent risks of traditional surgical biopsies. They make it easy to detect and monitor the progress of treatment and relapse, especially in scenarios where standard biopsies are difficult or dangerous. The need for personalised cancer therapy and precision medicine also contributes to the increased adoption of liquid biopsy panels, which makes them even more significant in the management of the rising cancer burden.

Will technological advancements in biomarker detection enhance liquid biopsy growth?

The use of technological upgrades in detecting the biomarkers is extremely helpful in boosting the development of the liquid biopsy panels market. Advanced profiling, next-generation sequencing (NGS), and other blood-based biomarker-detecting innovations have enhanced sensitivity and accuracy to detect circulating tumour DNA (ctDNA) and other biomarkers in a blood sample. Liquid biopsies promise to detect cancer at an earlier and less invasive stage than conventional tissue biopsies and even more efficiently, the National Cancer Institute (NCI) says. Another way the NCI points out is doing the treatment response and even spotting a recurrence even more precisely by enhanced detection of biomarkers using liquid biopsies.

The National Institute of Health (NIH) published studies showing that there is a marked solution to isolate and quantify rare biomarkers due to advancements in digital PCR and microfluidic technologies, which were impossible to identify due to low levels of biomarkers. Such technological advances have increased the clinical application of liquid biopsies beyond cancer into the field of prenatal and infectious testing. Altogether, the research supported by the government proves that the development of superior biomarker detection technologies is one of the key factors that drive the active integration of panels of liquid biopsies in the sphere of personalised medicine.

Are regulatory challenges slowing approval of liquid biopsy diagnostic tests?

Liquid biopsy diagnostic tests are still beset with regulations and slow in approval and adoption in clinical practice. The U.S. Food and Drug Administration (FDA) is demanding the rigour of clinical validation with the rules aiming at making them safe and effective, a factor that has contributed to long approval times. As per the report of the FDA released in 2023 on medical device approval, there has been a delay in the approval of novel in vitro diagnostics, since more attention is paid to them due to the essential nature of precision in cancer diagnostic tests.

The shift of laboratory-developed tests (LDTs) into FDA-regulated devices promises to add even more complexity, so the manufacturers must adhere to much stronger standards of analytical and clinical performance. In the European Union, the In Vitro Diagnostic Regulation (IVDR), which has been in force since May 2022, requires full clinical evidence and conformity checks, some of which are deemed resource-demanding by many developers.

National Cancer Institute (NCI) research studies mention that these regulatory requirements necessary for patient safety delay the availability of potentially useful liquid biopsy technologies for years of use in normal clinical practice. This duo of moving laws and the necessity of solid clinical data is also quite a big market inhibitor.

Can integration of AI improve accuracy of liquid biopsy panels?

The application of AI may play an important role in enhancing the accuracy of liquid biopsy panels by augmenting the interpretation and detection of complex genomic reads in blood samples. Machine learning-based AI algorithms have the potential to interpret massive volumes of sequencing data to detect subtle mutations, rare circulating tumour DNA (ctDNA), and other biomarkers that may be overlooked by more conventional approaches. For instance, a research study published by the National Cancer Institute (NCI) showed that the AI-based models increased the sensitivity and specificity of ctDNA detection by more than 15%, making the difference between false positives and early cancer detection.

The U.S. Food and Drug Administration (FDA) has identified the utility of AI in improving diagnostic accuracy, which facilitates regulatory courses on AI-augmented liquid biopsies. AI can also be included in liquid biopsy panels to provide more dependable personalised cancer tracking and prognosis, which eventually enhances clinical diagnosis and management of patients. The combination of AI and liquid biopsy technology is one of the potential breakthroughs in the diagnostics of non-invasively treated cancer.

Are partnerships with pharmaceutical companies expanding liquid biopsy applications?

Liquid biopsy applications have experienced progress as a result of partnerships between pharmaceutical companies and research institutions. These partnerships aim at enhancing the early detection of cancer, tracking responses to treatment, and customising therapy by examining tumour-derived circulating biomarkers in blood. The National Cancer Institute (NCI) announced that projects such as the Early Detection Research Network (EDRN) are currently promoting actions to help make cancer detection less invasive and more convenient, which involves the creation and verification of liquid biopsy technologies.

Academic medical institutions like Memorial Sloan Kettering Cancer Centre have collaborated with pharmaceutical companies to incorporate liquid biopsy assays in clinical trials of drug development and stratification of patients. Regulatory routes, including those of the U.S. Food and Drug Administration (FDA), have been streamlined in the case of liquid biopsy-based companion diagnostics, another indication of the confidence in these technologies. These government-sponsored programs and academia-industry collaborations are extending the clinical value of liquid biopsies that will lead to increased personalised and time-sensitive cancer care.

What are the key market segments in the Liquid Biopsy Panels industry?

Based on the Biomarker type, the Liquid Biopsy Panels Market has been classified into Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Exosomes & Extracellular Vesicles (EVs), MicroRNA, Cell-free DNA, Proteins, and Methylated DNA Markers. Circulating tumour DNA (ctDNA) is the most significant biomarker type in the liquid biopsy panels market. It offers a minimally invasive method of detecting genetic changes, monitoring the progression of tumours, and assessing the effects of treatment in real time. This has made it a key instrument in precision oncology due to its clinical application of early cancer detection, choice of therapy, and surveillance of relapse of the disease.

In comparison with other biomarkers, such as exosomes or CTCs, ctDNA is easier to isolate and analyse with high sensitivity due to novel sequencing technology. That has contributed to ctDNA becoming the prevailing force in research and clinical practices in the liquid biopsy subspace.

Based on the Panel Type, the Liquid Biopsy Panels Market has been classified into Single-Gene Panels, Multi-Gene Panels, Tumor-Specific Panels, Comprehensive Genomic Panels, and Custom Panels. The dominant part of the liquid biopsy panels market is the multi-gene panels. Such panels enable the analysis of many of the genes related to cancer at the same time, providing a wider picture of tumour genetics than do single-gene and tumour-specific panels. This capability to detect multiple mutations in a single test renders them very useful in terms of designing individual treatment plans and monitoring. Due to the advent of precision oncology, medical professionals are showing an increasing tendency to use multi-gene panels, as they are efficient, cost-effective choices regarding the overall diagnostic power. It has made them dominant both clinically and in research functions.

Which regions are leading the Liquid Biopsy Panels market, and why?

The North American liquid biopsy panel market has the largest share and has better healthcare facilities, with a substantial investment in research and development. The existence of significant biotechnology and pharmaceutical companies in the area spurs the development and commercialisation of the innovative liquid biopsy technologies. The popularisation of precision medicine and the growing cancer prevalence rate demand the implementation of noninvasive diagnostic methods such as the liquid biopsy panel.

Strength in regulatory guidelines and positive reimbursement policies also gives the market a boost. The level of awareness about early cancer diagnosis and individual treatment measures among citizens and medical workers is rather high, which makes North America take the leading place on the market. Close cooperation between the industry and educational institutions promotes active technological development as well.

The Asia Pacific liquid biopsy panels market is growing due to rapid growth in healthcare infrastructure, rising awareness of non-invasive diagnostic methods, and rising investments in biotechnology and molecular diagnostics. Increasing cases of cancer and other persistent health issues in India, China, and Japan, among other nations, are necessitating early and precise validation of cancer diagnosis, a factor that makes the liquid biopsy panel very topical.

The supportive role of governmental initiatives in developing the idea of cancer investigations and positive reimbursement policies adds to the growth of the market. The availability of a high number of patients and an increasing use of personalised medicine in this region are boosting liquid biopsy technology uptake, making this region a market leader around the world. Industry synergies between local biotechnology companies and international organisations are also increasing innovativeness and accessibility in this industry.

What does the competitive landscape of the Liquid Biopsy Panels market look like?

The liquid biopsy panels market is very competitive, as the technological development is very fast and its application in cancer therapy and personalised medicine is growing. Major vendors like Guardant Health, Roche Group, Illumina, and Natera are still playing the leading roles in revolutionising the market by offering innovative solutions to enhance detection and monitoring of cancer. This has involved recent strategic tie-ups and expansions of the product pipeline, with Guardant Health enhancing its position through tie-ups to improve its testing capabilities and Roche concentrating on integrating liquid biopsy assays and its other diagnostic platforms.

Technology companies such as Freenome and Exact Sciences are pouring a lot of money into research, trying to expand the uses of liquid biopsies to fields such as early disease detection or monitoring minimal residual disease. The result of this competitive environment is the constant breaking of new frontiers, and liquid biopsy is a seemingly more acceptable option compared to the conventional tissue biopsies.

Liquid Biopsy Panels Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Liquid Biopsy Panels industry?

• In May 2025, NHS England launched a new blood-based liquid biopsy program for lung and advanced breast cancer patients. The program used Guardant Health and Roche technologies. Since April, over 2,000 patients were tested. This helped reduce the diagnosis-to-treatment time by about 16 days.

Report Coverage:

By Biomarker Type

• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Exosomes & Extracellular Vesicles (EVs)
• MicroRNA
• Cell-free DNA
• Proteins
• Methylated DNA Markers

By Panel Type

• Single-Gene Panels
• Multi-Gene Panels
• Tumor-Specific Panels
• Comprehensive Genomic Panels
• Custom Panels

By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Beads, Emulsion, Amplification, and Magnetics
• Droplet Digital PCR
• Massively Parallel Sequencing
• Microarrays
• Immunoassays

By Application

• Cancer Diagnostics
• Treatment Selection & Monitoring
• Early Cancer Screening & Risk Assessment
• Recurrence & Prognosis Prediction
• Prenatal Testing
• Transplant Rejection Monitoring
• Infectious Disease Monitoring

By Sample Type

• Blood
• Urine
• Saliva
• Cerebrospinal Fluid
• Others

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Biopharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Guardant Health, Inc.
• Freenome Holdings, Inc.
• Exact Sciences Corporation
• Natera, Inc.
• Illumina, Inc.
• Sysmex Corporation
• Biocept, Inc.
• Roche Holding AG
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Adaptive Biotechnologies Corporation
• Personal Genome Diagnostics, Inc.
• MolecularMD, Inc.
• Sysmex Corporation

Frequently Asked Questions (FAQs)